Transforming Diabetes Care Through Artificial Intelligence: The Future Is Here

Irene Dankwa-Mullan, Marc Rivo, Marisol Sepulveda, Yoonyoung Park, Jane Snowdon, Kyu Rhee, Irene Dankwa-Mullan, Marc Rivo, Marisol Sepulveda, Yoonyoung Park, Jane Snowdon, Kyu Rhee

Abstract

An estimated 425 million people globally have diabetes, accounting for 12% of the world's health expenditures, and yet 1 in 2 persons remain undiagnosed and untreated. Applications of artificial intelligence (AI) and cognitive computing offer promise in diabetes care. The purpose of this article is to better understand what AI advances may be relevant today to persons with diabetes (PWDs), their clinicians, family, and caregivers. The authors conducted a predefined, online PubMed search of publicly available sources of information from 2009 onward using the search terms "diabetes" and "artificial intelligence." The study included clinically-relevant, high-impact articles, and excluded articles whose purpose was technical in nature. A total of 450 published diabetes and AI articles met the inclusion criteria. The studies represent a diverse and complex set of innovative approaches that aim to transform diabetes care in 4 main areas: automated retinal screening, clinical decision support, predictive population risk stratification, and patient self-management tools. Many of these new AI-powered retinal imaging systems, predictive modeling programs, glucose sensors, insulin pumps, smartphone applications, and other decision-support aids are on the market today with more on the way. AI applications have the potential to transform diabetes care and help millions of PWDs to achieve better blood glucose control, reduce hypoglycemic episodes, and reduce diabetes comorbidities and complications. AI applications offer greater accuracy, efficiency, ease of use, and satisfaction for PWDs, their clinicians, family, and caregivers.

Keywords: artificial intelligence; artificial pancreas; cognitive computing; diabetes care; glucose monitoring; retinal imaging.

Conflict of interest statement

Drs. Dankwa-Mullan, Park, Snowdon, and Rhee declare that there are no conflicts of interest. Drs. Rivo and Sepulveda received consulting fees from IBM Watson Health during the conduct of the study. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The views expressed in this article are the authors' own and not an official position of IBM.

References

    1. International Diabetes Federation (IDF). IDF diabetes atlas, 7th edition. Brussels, Belgium: International Diabetes Federation, 2015
    1. Liu J, Wang R, Ganz ML, Paprocki Y, Schneider D, Weatherall J. The burden of severe hypoglycemia in type 2 diabetes. Curr Med Res Opin 2018;34:179–186
    1. Centers for Disease Control and Prevention. Estimates of diabetes and its burden in the United States. Washington, DC: US Department of Health and Human Services, 2017:1–20
    1. The Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986
    1. Latts L. ADA/IBM Watson Health Study (N>300,000) finds that nearly 60% of people with T2D discontinue therapy after one year. Presented at: American Diabetes Association 78th Scientific Session, June 22–26, 2018, Orlando, FL
    1. National Center for Biotechnology Information; US National Library of Medicine. PubMed. Accessed July18, 2018
    1. Lewis K. Humans and systems: creating natural interfaces to augment human ability. Accessed July18, 2018
    1. Aggarwal M, Madhukar M. IBM's Watson analytics for health care: a miracle made true. Hershey, PA: IGI Global, 2016:117–134
    1. Turing Archive for the History of Computing. Accessed July18, 2018
    1. Research 2 Guidance. Top 3 therapy fields with the best market potential for digital health apps. Accessed July18, 2018
    1. Yeung S, Downing NL, Fei-Fei L, Milstein A. Bedside computer vision—moving artificial intelligence from driver assistance to patient safety. N Engl J Med 2018;378:1271–1273
    1. Young K. Newly approved software uses AI to improve diabetic retinopathy. Accessed July18, 2018
    1. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:45e
    1. López B, Martin C, Viñas PH. Special section on artificial intelligence for diabetes. Artif Intell Med 2018;85:27–28
    1. Raghupathi W, Raghupathi V. Big data analytics in healthcare: promise and potential. Health Inf Sci Syst 2014;2:3.
    1. Hoyt RE, Snider D, Thompson C, Mantravadi S. IBM Watson analytics: automating visualization, descriptive, and predictive statistics. JMIR Public Heal Surveill 2016;2:e157
    1. Vijan S, Hofer TP, Hayward RA. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA 2000;283:889–896
    1. Gulshan V, Peng L, Coram M, et al. . Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs. JAMA 2016;316:2402–2410
    1. Tariq A, Akram MU, Shaukat A, Khan SA. Automated detection and grading of diabetic maculopathy in digital retinal images. J Digit Imaging 2013;26:803–812
    1. Rahim SS, Palade V, Shuttleworth J, Jayne C. Automatic screening and classification of diabetic retinopathy fundus images. In: Mladenov V, Jayne C, Iliadis L, eds. Engineering applications of neural networks. Communications in computer and information science. Vol 459 Basel, Switzerland: Springer Nature Switzerland AG, 2014:113–122
    1. Lam C, Yu C, Huang L, Rubin D. Retinal lesion detection with deep learning using image patches. Invest Ophthalmol Vis Sci 2018;59:590–596
    1. US Food and Drug Administration. FDA permits marketing of artificial intelligence-based device to detect certain diabetes-related eye problems. Accessed July18, 2018
    1. Keel S, Lee PY, Scheetz J, et al. . Feasibility and patient acceptability of a novel artificial intelligence-based screening model for diabetic retinopathy at endocrinology outpatient services: a pilot study. Sci Rep 2018;8:4330.
    1. Matimba A, Woodward R, Tambo E, Ramsay M, Gwanzura L, Guramatunhu S. Tele-ophthalmology: opportunities for improving diabetes eye care in resource- and specialist-limited Sub-Saharan African countries. J Telemed Telecare 2016;22:311–316
    1. Han L, Luo S, Yu J, Pan L, Chen S. Rule extraction from support vector machines using ensemble learning approach: an application for diagnosis of diabetes. IEEE J Biomed Health Inform 2015;19:728–734
    1. Shankaracharya, Odedra D, Samanta S, Vidyarthi AS. Computational intelligence-based diagnosis tool for the detection of prediabetes and type 2 diabetes in India. Rev Diabet Stud 2012;9:55–62
    1. Wei W-Q, Tao C, Jiang G, Chute CG. A high throughput semantic concept frequency based approach for patient identification: a case study using type 2 diabetes mellitus clinical notes. AMIA Annu Symp Proc 2010;2010:857–861
    1. Corey KE, Kartoun U, Zheng H, Shaw SY. Development and validation of an algorithm to identify nonalcoholic fatty liver disease in the electronic medical record. Dig Dis Sci 2016;61:913–919
    1. Neves J, Martins MR, Vilhena J, et al. . A soft computing approach to kidney diseases evaluation. J Med Syst 2015;39:131.
    1. Rau H-H, Hsu C-Y, Lin Y-A, et al. . Development of a web-based liver cancer prediction model for type II diabetes patients by using an artificial neural network. Comput Methods Programs Biomed 2016;125:58–65
    1. Weber C, Neeser K. Using individualized predictive disease modeling to identify patients with the potential to benefit from a disease management program for diabetes mellitus. Dis Manag 2006;9:242–256
    1. Vyas R, Bapat S, Jain E, Karthikeyan M, Tambe S, Kulkarni BD. Building and analysis of protein-protein interactions related to diabetes mellitus using support vector machine, biomedical text mining and network analysis. Comput Biol Chem 2016;65:37–44
    1. López B, Torrent-Fontbona F, Viñas R, Fernández-Real JM. Single nucleotide polymorphism relevance learning with random forests for type 2 diabetes risk prediction. Artif Intell Med 2018;85:43–49
    1. Lo-Ciganic WH, Donohue JM, Thorpe JM, et al. . Using machine learning to examine medication adherence thresholds and risk of hospitalization. Med Care 2015;53:720–728
    1. Shu T, Zhang B, Yan Tang Y. An extensive analysis of various texture feature extractors to detect diabetes mellitus using facial specific regions. Comput Biol Med 2017;83:69–83
    1. Katigari MR, Ayatollahi H, Malek M, Haghighi MK. Fuzzy expert system for diagnosing diabetic neuropathy. World J Diabetes 2017;8:80–88
    1. Wang L, Pedersen PC, Agu E, Strong DiM, Tulu B. Area determination of diabetic foot ulcer images using a cascaded two-wtage SVM-based classification. IEEE Trans Biomed Eng 2017;64:2098–2109
    1. Mauseth R, Lord SM, Hirsch IB, Kircher RC, Matheson DP, Greenbaum CJ. Stress testing of an artificial pancreas system with pizza and exercise leads to improvements in the system's fuzzy logic controller. J Diabetes Sci Technol 2015;9:1253–1259
    1. Ling SH, Nguyen HT. Natural occurrence of nocturnal hypoglycemia detection using hybrid particle swarm optimized fuzzy reasoning model. Artif Intell Med 2012;55:177–184
    1. Herrero P, Pesl P, Reddy M, Oliver N, Georgiou P, Toumazou C. Advanced insulin bolus advisor based on run-to-run control and case-based reasoning. IEEE J Biomed Health Inform 2015;19:1087–1096
    1. DeJournett L, DeJournett J. In silico testing of an artificial-intelligence-based artificial pancreas designed for use in the intensive care unit setting. J Diabetes Sci Technol 2016;10:1360–1371
    1. Thabit H, Tauschmann M, Allen JM, et al. . Home use of an artificial beta cell in type 1 diabetes. N Engl J Med 2015;373:2129–2140
    1. Trevitt S, Simpson S, Wood A. Artificial pancreas device systems for the closed-loop control of type 1 diabetes: what systems are in development? J Diabetes Sci Technol 2016;10:714–723
    1. Zhang W, Yu Q, Siddiquie B, Divakaran A, Sawhney H. “Snap-n-Eat”: food recognition and nutrition estimation on a smartphone. J Diabetes Sci Technol 2015;9:525–533
    1. Cvetković B, Janko V, Romero AE, Kafalı Ö, Stathis K, Luštrek M. Activity recognition for diabetic patients using a smartphone. J Med Syst 2016;40:256.
    1. Wang L, Pedersen PC, Strong DM, Tulu B, Agu E, Ignotz R. Smartphone-based wound assessment system for patients with diabetes. IEEE Trans Biomed Eng 2015;62:477–488
    1. Rigla M, Martínez-Sarriegui I, García-Sáez G, Pons B, Hernando ME. Gestational diabetes management using smart mobile telemedicine. J Diabetes Sci Technol 2018;12:260–264
    1. Adult accuracy study of the Elite 3 Glucose Censor (E3). Accessed July18, 2018
    1. Neemuchwala H. improves time-in-range by 36 mins/day, time >180 by 30 mins/day, time <70 by 6 mins/day. Presented at: American Diabetes Association 78th Scientific Session, June 22–26, 2018, Orlando, FL
    1. Benson T. Principles of health interoperability HL7 and SNOMED, 2nd edition. London: Springer Verlag, 2012.
    1. Adler-Milstein J, DesRoches CM, Kralovec P, et al. . Electronic health record adoption in us hospitals: Progress continues, but challenges persist. Health Aff (Millwood) 2015;34:2174–2180
    1. Hutson TM. Missing data hinder replication of artificial intelligence studies. Accessed July18, 2018

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir